home / stock / xncr / xncr news

XNCR News and Press, Xencor Inc. From 02/20/19

Stock Information
Company Name: Xencor Inc.
Stock Symbol: XNCR
Market: NASDAQ
Website: xencor.com
Menu
XNCR XNCR Quote XNCR Short XNCR News XNCR Articles XNCR Message Board
Get XNCR Alerts

News, Short Squeeze, Breakout and More Instantly...
XNCR - Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045

MONROVIA, Calif. , Feb. 20, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the U.S. Food and ...
XNCR - Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019

MONROVIA, Calif. , Feb. 19, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it will re...

XNCR - Xencor to Present at Upcoming Investor Conferences

MONROVIA, Calif. , Feb. 7, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company man...

XNCR - Xencor up 4% on Roche deal

Thinly traded Xencor ( XNCR +3.5% ) is up below-average volume in response to its license agreement with Roche's ( OTCQX:RHHBY +0.6% ) Genentech aimed at developing and commercializing novel IL-15 cytokine therapeutics, including XNCR's XmAb24306. More news on: Xencor, Inc., Roche Ho...
XNCR - Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech

MONROVIA, Calif. , Feb. 5, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease, and cancer, today announced it has entered into a ...

XNCR - Positive And Negative Forensic Value Stock Selections - February

Forensic Value Stock Selections The following stock selections using three forensic algorithms from the financial literature rely exclusively on fundamental data and year-over-year operational performance measures. The combination of all three bankruptcy and financial irregularity algorithms...

XNCR - Report: Developing Opportunities within ONEOK, Alaska Air Group, Comcast, Mack-Cali Realty, Vistra Energy, and Xencor - Future Expectations, Projections Moving into 2019

NEW YORK, Jan. 28, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ONEOK, Inc. (NYSE:OKE), Alaska Air Group, Inc. (NYSE:ALK), Comcast Corpor...
XNCR - Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody

MONROVIA, Calif. , Jan. 7, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease and cancer, today announced it will regain rights to dev...

XNCR - Xencor to Present at 30th Annual Piper Jaffray Healthcare Conference

MONROVIA, Calif. , Nov. 20, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat...

XNCR - Xencor Q3 revenues $29M

Xencor (NASDAQ: XNCR ) Q3 results ($M): Revenues: 29.0 (from Novartis collaboration and $9M in milestone payments from Alexion). More news on: Xencor, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...

Previous 10 Next 10